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Abstract
A retrospective  study  on  healthy,  unrelated  subjects  was  conducted  in  order  to  estimate 
population glutathione-S-transferases  (GST) genotype frequencies  in  Slovak population of 
men and compare our results with already published data (GSEC project) [1]. A further aim 
of the study was to evaluate frequencies  of the  GST polymorphisms  also in patients with 
prostate cancer in order to compare the evaluated proportions with those found in the control 
subjects. Analysis for the GST gene polymorphisms was performed by PCR and PCR-RFLP. 
We  found  that  the  proportions  are  not  significantly  different  from  those  estimated  in  a 
European multicentre study or from the results published by another group in Slovakia. We 
found significantly increased age-standardized prostate cancer prevalence rates in the carriers 
of GSTM1 null genotype (P = 0.037) and trend for such an increase in the carriers of GSTP1 
polymorphism  when  compared  with  the  respective  groups  of  non-carriers.  Because 
understanding of the contribution of  GST gene polymorphisms and their  interactions with 
other  relevant  factors  may  improve  screening  diagnostic  assays  for  prostate  cancer,  we 
discuss issues of study feasibility, study design, and statistical power, which should be taken 
into account in planning further trials. 
Key words: glutathine-S-transferase, polymorphism, prostate cancer, slovak population.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
55
9.
1 
: P
os
te
d 
24
 N
ov
 2
00
8
Introduction
Prostate cancer is the most common cancer among men in industrialized countries with the 
main risk factor being age over 50. Prostate cancer is uncommon in men less than 45, but 
becomes more common with advancing age. The average age at the time of diagnosis is 65 [
2-4]. Since early detection increases survival rate, the prostate-specific antigen (PSA) test and 
the digital rectal examination should be offered to men annually beginning at age 50. Men at 
high risk should begin testing at age 45. The only well-established risk factors for prostate 
cancer are age, ethnicity, and family history of prostate cancer. However, research in the past 
few years  has  shown that  genetic,  social  and environmental  factors,  particularly  diet  and 
lifestyle, likely have an effect as well. It is assumed that increased exposure to procarcinogens 
and carcinogens contained in tobacco smoke, debris, fermented food, polluted water, air etc., 
is implicated in multistage carcinogenesis.  Therefore assessment of prostate  cancer hazard 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
55
9.
1 
: P
os
te
d 
24
 N
ov
 2
00
8
from environmental  pollution is  of  increasing  importance  and inherited  differences in  the 
effectiveness of detoxification/activation of carcinogens might play a role in deciding why one 
man might be at higher risk than another. The GSTM1, GSTT1 and GSTP1 members of the 
glutathione-S-transferase (GST) multigene family are candidate cancer-predisposing genes, 
since they are mostly involved in the detoxification of a wide range of environmental and 
tobacco carcinogens, endogenously produced reactive oxygen species and lipid peroxidation 
products.
 GSTs are phase II enzymes which are responsible for catalyzing the biotransformation of a 
variety of electrophilic compounds, and have therefore a central role in the detoxification of 
activated  metabolites  of  procarcinogens  produced  by  phase  I  reactions  [5].  Relation  of 
polymorphisms  in  these  genes to  chemical  carcinogenesis has been extensively  studied in 
various populations. Several population-based studies have reported prevalence ranging from 
47  to  58%  for  the  GSTM1 deletion  genotype  and  from  13  to  25%  for  the  GSTT1-null 
genotype among white Europeans  [1,6].  For  GSTP1,  the found prevalence rates of  Ile/Val 
heterozygosity  and  Val/Val homozygosity  were  between  (38  -  45.7)  % and (7  to  13)  % 
respectively [7].
Normal or increased GSTs enzyme activity or levels may protect susceptible tissues from 
somatic  mutation  in  DNA  by  facilitating  conjugation  and  subsequent  elimination  of 
electrophilic carcinogens. Absent or deficient GST enzyme activity can therefore result  in 
worsened elimination of electrophilic carcinogens, particularly in the presence of very active 
electrophilic  activation  by  phase  I  enzymes.  GST deficiencies  might  increase  the  risk  of 
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somatic mutation, which subsequently leads to tumor formation [6]. The absence of GSTM1 
activity is caused by inheritance of two null alleles (alleles that have a deletion of the GSTM1 
gene) similarly; individuals with no GSTT1 activity also have inherited null alleles of the 
GSTT1 gene. A single nucleotide polymorphism in the GSTP1 gene causes the substitution of 
isoleucine for  valine at  amino acid codon 105 (Ile105Val)  substantially  diminishes GSTP1 
enzyme activity and lessen effective capacity for detoxification [8,9]. However, the published 
data about the association of GSTs polymorphism and susceptibility to prostate cancer are 
controversial. Some studies suggest that the GSTM1, GSTT1 and GSTP1 polymorphisms are 
associated  with  prostate  cancer  susceptibility  [10,11],  whereas  other  studies  report  no 
association [12,13].
The aims of this study were: 1) to estimate population prevalence of the GSTM1, GSTT1 and 
GSTP1 gene polymorphisms in Slovak population of men and compare these results with the 
data  published  by  other  groups  (GSEC project – Genetic  Susceptibility  to  Environmental 
Carcinogens);  2)  to  evaluate  frequencies  of  the  GSTT1  and  GSTM1  null  genotypes  and 
polymorphisms in  GSTP1  also in the patients with prostate cancer in order to compare the 
evaluated proportions with those found in the age-standardized controls; and  3) to examine 
age-related differences in the frequency  distribution of  GST polymorphisms in the patients 
with prostate cancer. 
PATIENTS AND METHODS
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Study population
Blood samples from 228 subjects were obtained from healthy, unrelated subjects living in the 
north-western part of Slovakia, who were invited to attend the Department of Urology for 
regular prostate cancer screening between May 2005 and June 2007. The sample (median age 
of 63, IQR 56-70 years) was used for estimating population GST gene frequencies. 
The  second  part  of  the  study  was  designed  as  a  case-control study  (approximately  two 
controls  per  one case). A total  of 129 prostate  cancer  patients  with histologically verified 
prostate cancer (median age of 70, IQR 63-74 years) were invited to participate in the project 
and after signing  The informed consent document they were subjected to  GST genotyping. 
The inclusion criteria for the controls were the absence of any previous history of cancer and 
the serological levels of PSA less than 4 ng/ml.
The present  study was performed  under  the  approval  of  the  Ethical  Boards  of  Jessenius 
School of Medicine, Comenius University. 
Chemicals
Proteinase K was obtained from AppliChem (DE). All the primers, chemicals used for PCR 
and restriction enzyme were purchased from Eppendorf (USA). All other chemicals used for 
DNA isolation were purchased from Sigma Co. (USA).
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Genotyping 
Peripheral  vein  blood was collected  in  10  ml  heparinized  tubes  and the  specimens  were 
immediately stored at  20°C for genotyping− . From both, cases and controls, genomic DNA 
was  isolated  from  peripheral  leukocytes  by  proteinase  K  digestion,  phenol/chloroform 
extraction and ethanol precipitation, dissolved in TE buffer (pH 7.5) and stored at 20°C until−  
genotype analysis.  
A multiplex polymerase chain reaction (PCR) method was used to detect either presence or 
absence of  GSTM1 and  GSTT1 genes in the genomic DNA samples simultaneously in the 
same  tube;  β-globin gene  was  co-amplified  and  used  as  an  internal  control  [14].  This 
technique does not distinguish between heterozygote and homozygote GSTM1- and GSTT1-
positive genotypes, but it conclusively identifies null genotype [15]. Genomic DNA (100 ng) 
was amplified in a total volume of 25 µl reaction mixture containing 25 pmol of each GST 
primers (GSTM1: forward 5'-GAA CTC CCT GAA AAG CTA AAG C-3' and reverse 5'GTT 
GGG CTC AAA TAT ACG GTG G-3'; GSTT1: forward 5'-TTC CTT ACT GGT CCT CAC 
ATC TC-3' and reverse 5'-TCA CCG GAT CAT GGC CAG CA- 3'); 25 pmol β-globin gene 
primers (forward 5'-CAA CTT CAT CCA CGT TCA CC-3' and reverse 5'-GAA GAG CCA 
AGG ACA GGT AC-3'); 200 µmol/l deoxynucleoside triphosphates; 1 U of Taq polymerase 
in 10 × PCR buffer composed of 16.6 mmol/l (NH4)2SO4 and 20.0 mmol/l MgCl2, pH 8.8. 
After initial denaturation for 3 min at 94°C, 39 cycles were performed for 1 min at 94°C 
(denaturation), for 1 min at 60°C (annealing) and for 1 min at 72°C (extension), followed by a 
final step for 5 min at 72°C. The GSTM1 (215-bp),  GSTT1 (480-bp) and  β-globin (268-bp) 
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amplified  products  were  visualized  by  electrophoresis  on  ethidium-bromide-stained  3% 
agarose  gel.  For  deletions  of  GSTM1 and  GST1 no  amplified  products  can  be  observed, 
whereas  the  β-globin specific fragment  confirms the presence of amplifiable  DNA in the 
reaction mixture. 
The  GSTP1  Ile105Val substitution  was  detected  using the  PCR-RFLP  approach  as  the 
substitution by guanine introduced restriction site that can be recognized by an endonuclease 
Alw26I.  PCR reactions  were  performed  in  a  total  volume 25  l of  a  solution  containingμ  
10 × PCR buffer (16.6 mmol/l (NH4)2SO4,  20.0 mmol/l MgCl2, pH 8.8, 1.2 l DMSO, 1.2μ  lμ 
DTT), 200 µmol/l deoxynucleoside triphosphates, 1 U of Taq DNA polymerase,  100 ng of 
genomic DNA and 25 pmol of GSTP1 primers (forward 5'-GTA GTT TGC CCA AGG TCA 
AG-3' and reverse 5'-AGC CAC CTG AGG GGT AAG-3'). The reaction started for 3 min at 
94 °C, followed by 5 cycles of PCR (cycle 1: 94°C for 15 s, 64°C for 30 s, and 72°C for 1 
min) during which the anneling temperature decreased by 1°C for each cycle. This step was 
followed by 30 cycles of denaturation (for 15 s at 94°C), annealing (for 30 s at 59 °C), and 
extension (for 1 min at 72°C).  A final polymerization step (for 5 min at 72°C) was carried out 
to complete the elongation process and yield a 442-bp fragment. A negative control (PCR 
without template) was included in each set of PCR reactions. Each PCR product (10 µl) was 
digested for 4 hours with restriction enzyme Alw26I (5 U) and electrophoresed on ethidium-
bromide-stained 1.5% agarose gel. The presence of the Ile/Ile allele was detected by 329-, and 
113-bp  fragments,  whereas the  Val/Val allele  was  confirmed  by  216-,  113-,  and  107-bp 
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fragments. The heterozygote Ile/Val allele was characterized by four fragments consisting of 
329, 216, 113 and 107 bp [7]. 
Statistics
Age is presented as median and interquartile range (IQR) because the data showed departures 
from  normality  (according  to  Shapiro-Wilk’s  test).  The  χ2 method  was  used  to  test 
frequencies of genotypes/allele in prostate cancer patients and controls. The odds ratios (OR), 
estimates of the relative risk, with 95% confidence intervals (CI) were computed to assess 
strengths of association of the genotypes with prostate cancer. All  P values cited are two-
sided  alternatives;  differences  with  P values  less  than  0.05  were  judged  as  statistically 
significant [16].
Results
Since previous reports suggest that there are no differences in  GSTM1, GSTT1 and  GSTP1 
allele  frequencies  by age and sex  [17],  we conducted a  retrospective  study on a selected 
population of men in order to examine whether the gene frequencies were consistent with 
research  findings  across  Europe.  Statistical  analysis  of  data  collected  from  a  survey  of 
community sample in the north-western part of Slovakia showed that our estimates were not 
significantly  different  from either  those  found in  Caucasian population by Garte  and co-
workers [1] or those found previously by a research group in Slovakia [1] (Table 1). 
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The second purpose of the study was based on suggestion that the GST polymorphism might 
be associated with increased susceptibility to prostate cancer. Because both the incidence and 
prevalence of prostate  cancer  increase rapidly towards the older  age, we standardized the 
genotype data to match the age distribution of the samples. Calculated chi-square for equality 
of mean column scores and Cramér's V yielded 0.506 and 0.023, respectively, which did not 
account for significant differences in the age-standardized GST frequencies between healthy 
subjects and those diagnosed with prostate cancer. Absence of any association between null 
genotypes or polymorphism in  GST and prostate  cancer was confirmed also by analyzing 
case-control groups. Table 2 shows the distribution of the GST genotypes among controls and 
prostate  cancer  patients.  The  patients  did  not  have  significantly  different  frequencies  in 
genotypes and alleles in comparison to controls. 
Neither  the  comprehensive  score,  a  pooled  value  indicating presence  at  least  one  variant 
allele, showed a significantly reduced or unchanged risk of prostate cancer (data not shown). 
Logistic regression with predictors: age and types of GST enzyme confirmed age as the only 
risk  factor  for  developing  prostate  cancer  (P  <  0.0001;  OR per  one  unit  change  in  age 
amounts to 1.07 (95% CI 1.04-1.1). Since the age distribution of prostate cancer prevalence 
first follows a sigmoid-like curve and then gradually declines towards higher age groups, we 
were interested whether the age distribution curves for GST genotypes followed the same age-
dependence in the patients with and without defected genes. We found out differences in the 
age  distributions  among  carriers  and  non-carriers  of  GST null  genotypes  with  respect  to 
prostate cancer prevalence. Therefore we conducted an indirect standardization in order to 
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adjust these two groups to age. We found significantly increased age-standardized prostate 
cancer prevalence rates in the carriers of GSTM1 null genotype (P = 0.037) and trend for such 
an increase in the carriers of  GSTP1 polymorphism towards the older age when compared 
with the respective groups of non-carriers.  The differences in the rates for  the carriers  of 
GSTT1 null genotype were not significant.
Discussion 
To assess possible association between GST gene polymorphisms and occurrence of prostate 
cancer in Slovakia, we had to infer from population estimates acquired in the first part of the 
study on a sample of 228 consecutive men who scheduled appointments in the Department of 
Urology.
It  is  known  that  allele  frequencies  of  the  metabolic  genes  are  not  equally  distributed 
throughout  the  human  population  but  follow  diverse  ethnic  and/or  geographic-specific 
patterns.  The percentage of individuals who do not express the GSTM1 enzyme due to a 
homozygous gene deletion is higher in Caucasians and Asians than in Africans. About 20% of 
Caucasians, 60% of Asians and 40% of Africans do not express the GSTT1 enzyme [1,18]. 
Our results on GSTM1- and GSTT1-null frequencies, 57% and 19.7%, respectively,  did not 
differ  significantly  either  from  the  values  obtained  previously  by  a  Slovakian  group  of 
researchers (51.2% and 18%, respectively) or from those published by other authors [1]. The 
prevalence rate of Ile/Val heterozygosity and Val/Val homozygosity was 51.8% in our control 
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subjects. This frequency is also similar to that seen in other studies that analyzed GSTP1 
polymorphism [19-21].
Our focusing on the possible link between polymorphism at the GSTP1, GSTM1 and GSTT1 
gene loci and susceptibility to prostate cancer stems from the findings that polymorphisms in 
the genes involved in Phase 1 activation and Phase 2 detoxification of carcinogens can alter 
prostate cancer susceptibility [22]. It has been suggested that genetic susceptibility may lead 
to a faster accumulation of DNA damage and to a higher carcinogens accumulation, resulting 
in an earlier onset of prostate cancer [23]. Some studies have reported a relationship between 
GST  variants  and  risk  of  prostate  cancer  [9,10,12,13,24].  Generally,  the  distribution  of 
genotypes is not related to the stage of disease at the time of diagnosis, tumor histology, or 
exact  site of  the  tumor.  Therefore  in  our  study  we  assumed  there  was  no  significant 
contribution of these factors to the observed frequencies. Investigation of the GSTP1 gene did 
not reveal any significant association between heterozygous GSTP1 genotype (Ile/Val)  and 
prostate cancer. However, our results suggest that  Val/Val genotype of  GSTP1 gene could 
modulate  the  risk  of  prostate  cancer,  even  if  this  association  did  not  reach  statistical 
significance. We should bear in mind that the inability to reject the null hypothesis could be 
due to low power of the test because of a relatively small sample size. Therefore, the lack of 
significance  does  not  necessarily  mean  equality  of  the  distributions.  It  is  plausible  that 
polymorphism at the GSTP1 locus can play an important role in the susceptibility to different 
types of cancer. Association of the GSTP1 Val allele with cancer could be expected since the 
conversion of the amino acid at  codon 105 from isoleucine to valine substantially lowers 
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activity of the altered enzyme. It has been predicted from molecular modelling that the amino 
acid at this site lies in a hydrophobic binding site for electrophile substrates and thus affects 
the substrate binding [23]. On the other hand, there are also studies which did not prove any 
independent effect of this type of polymorphism on the susceptibility for prostate cancer [26-
28]. 
The isoforms GSTM1 and GSTT1 have functional polymorphism in the form of homozygous 
deletion of either or both genes, which leads to loss of their phenotypic enzyme activities. 
Individuals vary in their ability to metabolize several DNA-damaging agents because of the 
polymorphism of these detoxifying enzymes  [6].  In the present study, we did not observe 
significantly  different  crude  rates  of  the  GSTM1 and  GSTT1 null  genotypes  in  the  men 
diagnosed with prostate cancer and those in the control group. However, when controlled for 
age, differences in prevalence of the disease between the carriers and non-carriers of GSTM1 
null  genotype  were  evidenced.  These  findings  imply  a  possibility  of  earlier  onset  of  the 
disease in the group of GST null-genotypes carriers. Investigations by the time of diagnosing 
of prostate cancer are needed to prove the hypothesis of earlier disease-onset in the carriers or 
at least to provide more scientific data and information.
Our data and data published by other researcher groups suggest that differences in the  GST 
frequencies between prostate cancer patients and control group are relatively small, therefore, 
it is difficult to separate the groups from each other based on statistical data analysis. Again, 
high variability in the groups could mask statistical differences due to low power. The easiest 
way how to  improve  precision  is  to  increase  the  number  of  subjects  and  patients  in  the 
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experimental design. However, this may not be applicable to all research conditions due to 
e.g. additional costs, poorer availability of resources, lower population, which compromises 
the number of subjects eligible for investigation. The possible ways how to achieve a power 
of at least 80% are to identify other explanatory variables and control for them, or to apply 
meta-analysis in order to increase sample size. 
Recent studies on GST polymorphism have also evaluated the combined effect of GSTM1 and 
GSTT1 genotypes, but most of them failed to show any significant association between the 
joint deficiency of these genes and prostate cancer risk [27,29]; to our knowledge, only one 
study has reported a significantly increased prevalence of prostate cancer among carriers of 
both GSTM1 and GSTT1 null genotypes [30]. Some studies, which combined data from other 
genotypes, have shown that the concurrent lack of GSTM1/GSTT1 and GSTP1 genes posed a 
significantly increased risk of prostate cancer  [21,31,32], however, this has not been proved 
by other authors [26]. One of the reasons for such discrepancy in the findings might lie in the 
difficulty  of  analyzing  impact  of  the  modified  GST activity  on  detoxification  of  known 
carcinogens. GST has overlapping substrate specificities; therefore deficiency of a single GST 
isoenzyme  may  be  compensated  by  the  other  isoforms.  Another  important  factor  is  the 
differential expression of genes for GST in the different cells.
Further,  reasons  for  the  inconsistency  in  results  among  various  studies  may  be  due  to 
differences  in  the  study  design,  target  populations,  as  well  as  in  the  environmental  or 
endogenous exposures. Many have taken for granted that exposure to carcinogens in polluted 
regions and/or smoking together with gene defect can trigger malignant transformation. 
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The  variation  in  published  prostate  cancer  prevalence rates  can  be  attributed  partly  to 
methodological  differences  in  survey  design,  including  age  distribution of  the  population 
surveyed. It is also known that prostate cancer incidence is underestimated, maybe due to 
poor compliance of elderly with screening recommendations. Thus,  regular follow-ups are 
difficult to achieve and, as a consequence, many men never know they have prostate cancer. It 
has  been  reported  that  calculated  prevalence  of  prostate  cancer  at  death  (i.e.  histological 
evidence) for a 60-year-old man is 32%, but the prevalence in living men (clinically-defined 
disease) is approximately 4% [33]. 
Finally, we will briefly mention two other considerations. Our results on differences in age 
distribution among carriers and non-carriers of  GST null genotypes pointed to an increased 
prevalence of prostate  cancer at  younger  age. This finding implies a possibility of earlier 
onset  of  the  disease  in  the  group  of  GST null-genotypes  carriers  even  if  the  overall 
frequencies  need  not  be  different  in  the  group  of  carriers  and  non-carriers.  The  second 
consideration is that, in contrast to the possible role of GST in environmental carcinogenesis, 
it  has  been  suggested  that  GST genotypes  conferring  lower  enzyme  activity  may  be  of 
advantage  for  the  patients  who are  undergoing  chemotherapeutic  treatment  for  neoplastic 
disease because reduced detoxification potentially enhances effectiveness of cytotoxic drugs [
34].  Although somewhat speculative, the  GST polymorphisms might be a protective factor 
during the period of chemotherapy, as the carriers of GST null genotypes might better respond 
to the treatment. At present, it is difficult to confidently evaluate GST polymorphisms impact 
on prostate cancer patients. Apparently, it would be far too simplistic to attribute a complex 
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problem such as prostate cancer to any single cause. Even if, methodologically, it is difficult 
to separate all interfering factors to identify individual changes, there is still a possibility of 
conducting  a  carefully  designed  international  and/or  multicentric  study,  or  of  combining 
results of several independent studies on the topic. 
In conclusion, our results speak for possible association between the GSTP1 Val/Val genotype 
and occurrence  of prostate  cancer;  however,  broad  confidence intervals  indicate  naturally 
high variability in GST polymorphisms in the population, which has given less weight to the 
observed differences in GSTP1 Val/Val genotype frequencies between the patients and control 
subjects 
Even if it showed that our study was not designed and powered to detect single gene effects, 
as well as gene-environment interactions, we cannot exclude that inter-individual differences 
in  GST  enzyme  activity  mediated  by  polymorphic  genes,  and  reflected  in  insufficient 
detoxification of environmental mutagens and carcinogens, may be involved in the pathway, 
ultimately leading to  tumor formation.  Because understanding of the contribution of  GST 
gene polymorphisms and their interactions with other relevant factors may improve screening 
diagnostic assays for prostate cancer, as well as clinical management of the patients, further 
studies are desirable to validate observed associations and to identify causal sequence for 
prostate cancer from GST gene polymorphisms, providing it exists. 
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Table 1 Frequencies of GST polymorphisms in the present study, in comparison to those of 
other studies conducted on Slovak and Caucasian populations.
Genotype frequencies of the GSTP1 gene in Caucasian population and our 
controls
Controls Caucasians Probability
Ile/Ile 110/228 (0.482) 498/1137 (0.438) 0.22
Ile/Val+Val/Val 118/228 (0.518) 561/1137 (0.493) 0.51
Frequency of GSTT1 null genotype in Caucasian population and our controls
45/228 (0.197) 1103/5577 (0.198) 0.99
Frequency of GSTM1 null genotype in Caucasian population and our controls
130/228 (0.57) 5583/10514 (0.531) 0.24
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Frequency of GSTT1 null genotype in Slovak population (GSEC) and our 
controls
45/228 (0.197) 60/332 (0.180) 0.62
Frequency of GSTM1 null genotype in Slovak population (GSEC) and our 
controls
130/228 (0.57) 170/332 (0.512) 0.18
Table 2 Distribution of GST genetic polymorphism in controls and patients with prostate 
cancer. 
Genotype frequencies of the GSTP1 gene in prostate cancer patients (cases) and 
controls
Controls Cases 95% CI for 
proportion difference
Probability
Ile/Ile 103 (0.452) 56 (0.434) -0.090 to 0.123 0.75
Ile/Val 118 (0.517) 67 (0.519) -0.109 to 0.104 0.97
Val/Val 7 (0.031) 6 (0.047) -0.084 to 0.012 0.44
Ile/Val + Val/Val 125 (0.48) 73 (0.566) -0.123 to 0.090 0.75
Frequency of GSTT1 null genotype
45 (0.197) 24 (0.186) -0.078 to 0.093 0.79
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Frequency of GSTM1 null genotype
130 (0.57) 69 (0.535) -0.071 to 0.142 0.52
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